Miriam Reyes

Executive Vice President of Operations

Miriam Reyes has 25 years of experience in life science and laboratory operations, and R&D. She has served as Operations Leader at MDxHealth since its US inception in 2011. Prior to MDxHealth, Mrs. Reyes was Director of Laboratory Operations at Agendia where she established/built and led the CLIA lab for the Agendia’s FDA cleared MammaPrint breast cancer test. In addition to Agendia, she established laboratory operations at Combimatrix (Invitae) Molecular Diagnostics and developed commercial assays at both IBIS Biosciences and US Labs (LabCorp.).

Mr. Jan Pensaert

Director, representing Valiance Advisors LLP

Jan Pensaert is the Founding Managing Partner of Valiance. He brings over 20 years of experience in growth investing. He leads the Investment Committee for the Valiance Funds and is responsible for all aspects of the Funds’ investment processes. Jan currently serves on the Board of several Valiance entities funds and portfolio companies including MDxHealth, JenaValve, MyCartis, and 4Tech. Prior to founding Valiance, Jan was CEO of La Fayette, where during his tenure the La Fayette Funds increased in AUM from $750 million to $5.5 billion. Before that, he was responsible for the Permal Group’s European-based investment management and research activities, and prior to that, he worked at Lazard in Corporate Finance M&A. Jan holds a BA in Business Economics from Gent University in Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille, France.

Regine Slagmulder

Independent Director, representing Regine Slagmulder BV

Regine Slagmulder P.h.D. is a partner and full professor in management accounting & control at Vlerick Business School. Previously, she worked as a strategy practice consultant at McKinsey & Company. She also previously worked as a professor of management accounting at INSEAD and at the University of Tilburg. Dr. Regine Slagmulder graduated in civil electrotechnical engineering and industrial management from the University of Ghent, after which she took a management doctorate at Vlerick Business School. As part of her research activities, she was a research fellow attached to INSEAD, Boston University (USA) and the P. Drucker Graduate Management Center at Claremont University (USA).

Mr. Rudi Mariën

Director, representing Biovest CVA

Rudi Mariën is currently Director of Biocartis S.A. (Swirtzeland). He is also President and CEO of Gengest Bvba and Biovest CommVa.  Through his management company, Gengest BVBA, Mr. Mariën has board mandates in different stock listed (Quest For Growth, Devgen… ) and private biotech companies (ActogenixNV, Pharmaneuroboost NV, Oystershell NV…).

Previously Mr. Mariën was founder, reference shareholder and managing director of Barc NV group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceuticals studies. He was also the co-founder, reference shareholder and chairman of the biotech company Innogenetics NV.

Mr. Koen Hoffman

Chairman and Independent Director

Koen Hoffman has served as Independent Chairman of the Board of Directors of Fagron NV since May 8, 2017. He obtained a Master in Applied Economics at the University of Ghent in 1990 and a Master in Business Administration at Vlerick Business School in Ghent in 1991. Mr. Hoffman was appointed Chief Executive Officer of Value Square in August 2016. Prior to joining Value Square, he was Chief Executive Officer of KBC Securities, member of the supervisory board of Patria Securities and member of the board of directors of Omnia Travel Belgium. He started his career at the corporate finance department of KBC Bank in 1992.

Eric Bednarski

Director

Eric Bednarski, Ph.D., serves as an Investment Manager and Partner at MVM Life Science Partners LLP, where he joined in 2008. Dr. Bednarski co-founded Prexa Pharmaceuticals, Inc. in 2006. Dr. Bednarski previously served as a Partner at Advent Healthcare Ventures. He was a Principal at Advent International Corporation, Advent Health Care & Life Sciences I, L.P. and Advent Health Care & Life Sciences III, L.P. Dr. Bednarski joined Advent’s healthcare and life sciences venture capital team in 2001. Previously, Dr. Bednarski served as an Executive Officer in the Corporate Finance Group at Silicon Valley Bank, Inc., where he advised venture backed life sciences companies on mergers and funding strategies. Dr. Bednarski also served in drug discovery group at DuPont-Merck Pharmaceutical Company. He serves as the Chairman at Tarsa Therapeutics, Inc. He has been a Director of BioTheranostics, Inc. since 2016. He serves as a Director of Solx, Inc. and AccuVein, LLC. He served as a Director of Heptares Therapeutics Ltd, Prexa Pharmaceuticals, Inc.

Joseph Sollee

Executive Vice President of Corporate Development and General Counsel

Mr. Sollee has more than 20 years of experience in the healthcare industry, including senior management roles in both private and publicly listed pharmaceuticals, health information technology and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Prior to MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&LGates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Masters degree in International Law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.

Ron Kalfus

Chief Financial Officer

Mr. Ron Kalfus has over 20 years of leadership experience in both public and private companies within diagnostics/biotech and other sectors, and brings extensive knowledge in financial operations and management. Mr. Kalfus joins MDxHealth from Rosetta Genomics, where he helped lead efforts to reposition the company for commercial success with its oncology diagnostic products, and raised over $60 million in capital to fund these efforts. Prior to Rosetta, Mr. Kalfus served as the CFO and Treasurer of MabCure, a Belgium-based publicly-traded biotechnology startup in the field of early cancer detection using antibodies.

Licensure & Accreditations

Michael K. McGarrity

Chief Executive Officer, Director

Mr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Michael was most recently the CEO of Sterilis Medical. Prior to Sterilis Michael was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, McGarrity spent 13 years at Stryker Corporation (NYSE: SYK). McGarrity served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. He also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Michael received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.

Timothy I. Still

Independent Director

Mr. Still has over 29 years of experience in medical devices and diagnostics. He has extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies. Mr. Still has been directly responsible for building the commercial viability at many of his previous companies, five of which have been successfully acquired (representing >$1.1B in proceeds). Mr. Still was most recently the President and CEO of Myoscience, located in Fremont, CA. Mr. Still was hired to develop a new commercial strategy at the company, and re-direct the technology platform into the pain management/orthopedic marketplace. While leading Myoscience, he raised over $12M in convertible debt, rebuilt the commercial organization, and successfully negotiated a strategic exit in the Spring of 2019. Myoscience was acquired by Pacira Pharmaceuticals for a valuation of ~40X trailing revenue in an industry known for valuation ranges of ~7X. Mr. Still received a B.S. degree (with Honors) in Biological Sciences from the University of California at Davis, and an MBA (Deans Scholar) in Marketing and Entrepreneurship from the University of Southern California.

Hilde Windels

Independent Director, representing Hilde Windels BVBA

Ms. Windels is the CEO of immunodiagnostic company Antelope Dx BV and has 20 years of experience in the biotechnology sector with a track record of building and structuring organizations, fundraising, M&A, public capital markets and corporate strategies. At Biocartis, she was CEO and interim and Deputy CEO from September 2015 until September 2017 and CFO from 2011 until September 2015. Previously, Mrs. Windels worked as an independent CFO for several private biotech companies, and from 1999 to 2008 she was CFO of Devgen. Currently, Mrs. Windels serves as a board member at Erytech and Celyad. In the past, she also served on the boards of Devgen, Biocartis, Ablynx, VIB, and FlandersBio. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.

John Baellano

Chief Commercial Officer

Mr. Bellano has more than 25 years of experience in the Healthcare Industry. Mr. Bellano started his career in Pharmaceuticals and transitioned to molecular diagnostics where he has spent the past 20 years of his career. Most recently the Chief Commercial Officer of Sterilis Solutions Prior to Sterilis Solutions he served as the commercial leader for Pharmacogenomic companies Assurex Health and AltheaDx. While at Assurex Health (Myriad Genetics) revenue grew from $700k to a run rate of $100 Million during his 5 year span with the organization.

How to Order SelectMDx

United States

Europe

How to Order ConfirmMDx

Physician Office

To Order Pre-printed Test Requisition Forms:

Order Supplies Online
Call 866.259.5644
Email client.services@mdxhealth.com

View and Download ConfirmMDx Test Requisition Form (TRF)
View and Download ConfirmMDx Specimen Requirements and Patient Eligibility

Pathology Laboratory

To order ConfirmMDx Tissue Transport Kits:

Order Supplies Online
Call 866.259.5644
Email client.services@mdxhealth.com

Insurance & Billing Policy

We are committed to making our tests accessible and affordable to your patients. MDxHealth’s Patient First Promise Program was created to assist patients throughout the billing process. We will work directly with each patient to ensure their complete satisfaction.

Dedicated Patient Advocate Team

Our specially trained Patient Advocates are ready to answer patients’ questions about insurance coverage and personalized payment options.
Toll Free: 866-259-7001, Monday – Friday, 6:00AM – 4:30PM PT
Email: patientfirst@mdxhealth.com

Personalized Payment Options

Prompt-Pay Discount
Interest-Free Payment Plan
Financial Assistance Program

Frequently Asked Questions

Will my insurance cover the test?

MDxHealth directly contracts with most insurance providers to obtain the best coverage possible. MDxHealth will submit a claim to your insurance company or Medicare for the test.

Depending on your insurance, you may be responsible for copayment, coinsurance, and/or deductible amounts according to your individual plan. If you have questions about coverage, please contact our Patient Advocate Team.

What is an Explanation of Benefits (EOB) statement?

Your insurance provider will send you a claim summary called an Explanation of Benefits (EOB). The EOB explains which medical services were covered by your insurance provider on your behalf. It is important to note the EOB IS NOT A BILL.

What if I don’t have insurance?

MDxHealth has self-pay options available. Please contact our Patient Advocate Team for more information.

Jean-Marc Roelandt

Chief Financial Officer

Mr. Sollee has more than 20 years of experience in the healthcare industry, including senior management roles in both private and publicly listed pharmaceuticals, health information technology and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Prior to MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&LGates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Masters degree in International Law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.

Lieve Verplancke MD.

Independent Director, representing Qaly-Co BVBA

Lieve Verplancke MD was nominated as an Independent Non-Executive Director at the Company’s Annual General shareholders Meeting held on 26 May 2017 in Diegem, Belgium. Ms. Verplancke, a Belgian national, began her career in 1984 with The Beecham Group (now part of GlaxoSmithKline), and has since held key management positions with Merck & Co., as well as Bristol-Myers Squibb, where she served as Managing Director, leading their Belgian/GDL subsidiary, until 2012. Ms. Verplancke has also served as a Board Member for Brussels-based Europe Hospitals; the Imelda Hospital in Bonheiden; and the Euronext fund, Quest for Growth and Materialise. She is also the Founder and Managing Director of Qaly@Beersel, an elderly care center in Belgium. In addition to being a medical doctor (MD – KULeuven University), Ms. Verplancke holds a postgraduate degree in Economics and an MBA from the University of Antwerp. She has also completed courses at INSEAD, CEDEP, Columbia University and the Vlerick Business School, and is a certified Executive Coach (PCC).

Test Cancellation Policy

MDxHealth will honor test cancellation requests any time prior to the start of the analytical testing phase. Test cancellation requests must be submitted from the person authorized to cancel a test, following the instructions below:

Contact Client Services at 866-259-5644 for test cancellation.

A Test Cancellation Form will be sent to the authorized person for signature.

Return the completed and signed Test Cancellation Form by fax to MDxHealth 949-788-0014.

If the cancellation request is received after the specimen has entered in the analytical testing phase, the request cannot be honored and the usual test charge will be assessed.

How to Order ConfirmMDx

View and Download ConfirmMDx Test Requisition Form

View and Download Specimen Requirements and Patient Eligibility

Physician Office:

Complete the ConfirmMDx test requisition form (TRF). Include patient demographics, copy of insurance card(s), and pathology report.
Forward the completed ConfirmMDx TRF to MDxHealth Client Services. MDxHealth will contact the pathology laboratory and request specimens as indicated on the TRF in “Section 7 – ConfirmMDx Specimen Request”.

Pathology Lab:

To order ConfirmMDx specimen transportation kits contact MDxHealth at 866.259.5644 or email client.services@mdxhealth.com
Pathology lab will include specimens, completed test requisition form (including copies of patient demographics, insurance, and pathology report) inside the transportation kit. Ship to: MDxHealth, 15279 Alton Parkway, Suite 100, Irvine, CA 92618.

Questions?

Contact MDxHealth Client Services:
Phone: 866.259.5644
Fax: 949.788.0014
Email: client.services@mdxhealth.com

Thank you! Your supply order had been submitted successfully. You will receive an email with confirmation within 24 hours.

Thank you! Your FedEx pick up request has been submitted successfully. You will receive an email confirmation within one hour during normal business hours (Monday – Friday, 6:00 a.m. – 5:00 p.m. PT)

Provider Terms of Use – SecureMDx

BY SIGNING UP FOR AN ACCOUNT OR BY ACCESSING OR USING SECUREMDX (THE “SITE”), YOU AGREE TO BE BOUND BY THESE PROVIDER TERMS OF USE (“Provider Terms”). Please read this carefully, and do not sign up for an account or use the Site if you are unwilling or unable to be bound by these Provider Terms.

Information, including Personal Health Information as defined in 45 CFR 160.501 (“PHI”), accessed and/or retrieved from the Site, is intended only for the review and/or use by authorized users for legitimate purposes. You may permit authorized members of your staff (your “Provider Group”) to use the Site, only under the following conditions:

Each member of your Provider Group must have a unique user ID and password, and you will provide MDxHealth the legal name, title and email address of each such member for whom you are seeking credentials;
Each member of your Provider Group must be trained on and comply with the requirements of these Provider Terms; and
You will immediately notify us of termination of employment or the withdrawal of authorization for any member of your Provider Group.

By accessing the Site, you and each member of your Provider Group (each, a “User”) agrees:

To use appropriate safeguards and practices to prevent the inappropriate use or disclosure of PHI and comply with all applicable federal and state laws and regulations which protect the confidentiality of PHI;
To mitigate, to the extent practicable, any harmful effect that is known to User of a use or disclosure of PHI in violation of the requirements of these Provider Terms and conditions; and
To promptly report to the MDxHealth Privacy Hotline (949-271-9252) any use or disclosure of PHI of which he/she becomes aware which would violate these provider Terms.

Access and/or retrieval of information from the Site for any other purpose is expressly prohibited. User’s access to the Site will be recorded electronically, and Users consent to having all or any part of their use of and access to the Site recorded audited or reviewed at any time.

Each User hereby agrees to indemnify, defend, and hold harmless MDxHealth (“MDxHealth,” we,” “our” or “us“) and any parent, subsidiary or affiliated entities, and our and their respective officers, directors, employees, and agents, from and against any claim, cost or liability, including reasonable attorneys’ fees, arising out of or relating to the use of the Site by you or any person gaining access to the Site under credentials assigned to you or a member of your Provider Group. In addition, you hereby release us and any parent, subsidiary or affiliated entities, our officers and employees, and officers and employees of any parent, subsidiary or affiliated entities from any and all claims, demands, debts, obligations, damages (actual or consequential), costs, and expenses of any kind or nature whatsoever, whether known or unknown, suspected or unsuspected, disclosed or undisclosed, that you may have against them arising out of or in any way related to such disputes and/or to any services or materials available at the Site. You hereby agree to waive all laws that may limit the efficacy of such releases.

In no event shall we be liable for any direct, indirect, special, punitive, incidental or consequential damages (including, without limitation, personal injury/wrongful death, lost profits, or damages resulting from lost data or business interruption) resulting from the use or inability to use the site, whether based on warranty, contract, tort, or any other legal theory, and whether or not we have been advised of the possibility of such damages.

The site is provided “as is” and without warranties of any kind either express or implied. to the fullest extent permissible pursuant to applicable law, we disclaim all warranties, express or implied, including, but not limited to, implied warranties of merchantability, fitness for a particular purpose, title and on-infringement. we do not warrant that the functions contained in the site will be uninterrupted or error-free, that defects will be corrected, or that the site or the server(s) that makes our site available or hyperlinked site are free of viruses or other harmful components or that our site, server(s) or hyperlinked sites will be accessible at all times.

We may update or change these Provider Terms from time to time and will post any updates or changes to these Provider Terms and the general Terms of Use on the Site. You understand and agree that your continued use of the Site after such terms have been updated or changed constitutes your acceptance thereof.

Thank you! Your request had been submitted successfully. You will receive an email with directions on how to set up your user ID and password within 24 hours.

About

Working With MDxHealth

Leadership

Michael K. McGarrity

Chief Executive Officer, Director

Ron Kalfus

Chief Financial Officer

John Bellano

Chief Commercial Officer

Miriam Reyes

Executive Vice President of Operations

Joseph Sollee

Executive Vice President of Corporate Development and General Counsel

Board of Directors

Koen Hoffman

Chairman and Independent Director

Eric Bednarski, Ph.D

Director

Rudi Mariën

Director, representing Biovest CVA

Michael K. McGarrity

Chief Executive Officer, Director

Jan Pensaert

Director, representing Valiance Advisors LLP

Regine Slagmulder

Independent Director, representing Regine Slagmulder BV

Timothy I. Still

Independent Director, representing TSTILL Enterprises LLC

Lieve Verplancke MD.

Independent Director, representing Qaly-Co BVBA

Hilde Windels

Independent Director, representing Hilde Windels BVBA

Clinical Research Network

Licensure & Accreditations

MDxHealth endeavors to meet and exceed industry standards for clinical laboratory testing.

Careers

Contact Us

Receive Updates from MDxHealth

MDxHealth

Physicians

Patients

Investors